Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human papillomavirus L1 virus-like particles vaccine NBP615
- Development stage
- Phase 2
- Lead developer
- SK bioscience
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
NBP615 is a human papillomavirus (HPV) vaccine composed of purified virus-like particles (VLPs) made from the major capsid (L1) proteins of HPV subtypes 6, 11, 16, and 18. It is designed for active immunization against these four HPV types. The vaccine is administered intramuscularly and aims to prevent diseases associated with these HPV strains, including cervical cancer and genital warts. NBP615 is being developed by SK Bioscience (a subsidiary of SK Chemicals), with its highest reported clinical development status as Phase 2 for the prevention or treatment of cervical cancer[1][2][3][4].
- Other names
- HPV L1 virus-like particles vaccine NBP615
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)
Beyond the preview
Go deeper on Human papillomavirus L1 virus-like particles vaccine NBP615.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human papillomavirus L1 virus-like particles vaccine NBP615.